Phase 1 Neuroendocrine Neoplasms Clinical Trials

6 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–6 of 6 trials

Recruiting

Phase 1

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Boehringer Ingelheim300 enrolled12 locationsNCT04429087

Recruiting

Phase 1

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

Boehringer Ingelheim55 enrolled19 locationsNCT06132113

Recruiting

Phase 1Phase 2

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors

National Cancer Institute (NCI)56 enrolled1 locationNCT04086485

Recruiting

Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Neuroendocrine NeoplasmNeuroendocrine TumorsSST2-positive Neuroendocrine Neoplasms

Crinetics Pharmaceuticals Inc.150 enrolled21 locationsNCT07129252

Recruiting

Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more

SystImmune Inc.120 enrolled20 locationsNCT07080242

Recruiting

Phase 1

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms

Boehringer Ingelheim12 enrolled1 locationNCT05963867